论文部分内容阅读
目的研究胸腺肽α1对脓毒症患者T细胞亚群等免疫功能的影响。方法随机将脓毒症患者40例分为治疗组(n=20)和对照组(n=20),对照组给予SSC(surviving sepisis campaign,SSC)经典治疗,治疗组则加用胸腺肽α1治疗,疗程为7d。分别观察两组患者治疗前后APACHEⅡ评分、CRP、T细胞亚群CD3+、CD4+、CD8+、CD4+/CD8+比值、NK细胞百分率、淋巴细胞计数的变化。结果脓毒症治疗组治疗后APACHEⅡ评分及CRP下降,CD3+、CD4+上升,CD8+下降,CD4+/CD8+上升,NK细胞百分率和淋巴细胞计数上升,与治疗前以及对照组治疗后相比差异有统计学意义(P<0.05)。结论胸腺肽α1可以改善脓毒症患者的免疫功能,调节炎症反应状态,有利于脓毒症的控制。
Objective To study the effect of thymosin α1 on immune function such as T cell subsets in sepsis patients. Methods Forty patients with sepsis were randomly divided into treatment group (n = 20) and control group (n = 20). The control group was treated with SSC (classic survivin sepsis campaign), while the treatment group was treated with thymosin α1 Treatment for 7d. The changes of APACHEⅡscore, CRP, T cell subsets CD3 +, CD4 +, CD8 +, CD4 + / CD8 + ratio, NK cell percentage and lymphocyte count were observed before and after treatment. Results APACHEⅡscore and CRP decreased, CD3 +, CD4 + increased, CD8 + decreased, CD4 + / CD8 + increased, NK cell percentage and lymphocyte count increased in the sepsis treatment group after treatment compared with those before treatment and in the control group Significance (P <0.05). Conclusions Thymosin α1 can improve the immune function of sepsis patients, regulate the inflammatory reaction status and facilitate the control of sepsis.